Mechanisms of therapy resistance in patient-derived xenograft models of BRCA1-deficient breast cancer
…, U Boon, M De Maaker, E Lips, L Mulder… - Journal of the …, 2016 - academic.oup.com
Background: Although BRCA1-deficient tumors are extremely sensitive to DNA-damaging
drugs and poly(ADP-ribose) polymerase (PARP) inhibitors, recurrences do occur and, …
drugs and poly(ADP-ribose) polymerase (PARP) inhibitors, recurrences do occur and, …
Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response
…, J Hannemann, H Halfwerk, L Mulder… - Breast cancer research …, 2010 - Springer
ER, PR and HER2 status in breast cancer are important markers for the selection of drug
therapy. By immunohistochemistry (IHC), three major breast cancer subtypes can be …
therapy. By immunohistochemistry (IHC), three major breast cancer subtypes can be …
[HTML][HTML] Genomic analysis defines clonal relationships of ductal carcinoma in situ and recurrent invasive breast cancer
Ductal carcinoma in situ (DCIS) is the most common form of preinvasive breast cancer and,
despite treatment, a small fraction (5–10%) of DCIS patients develop subsequent invasive …
despite treatment, a small fraction (5–10%) of DCIS patients develop subsequent invasive …
[HTML][HTML] Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy response
EH Lips, M Michaut, M Hoogstraat, L Mulder… - Breast Cancer …, 2015 - Springer
Introduction In triple negative breast cancers (TNBC) the initial response to chemotherapy is
often favorable, but relapse and chemotherapy resistance frequently occur in advanced …
often favorable, but relapse and chemotherapy resistance frequently occur in advanced …
SERPINA6, BEX1, AGTR1, SLC26A3, and LAPTM4B are markers of resistance to neoadjuvant chemotherapy in HER2-negative breast cancer
JJ De Ronde, EH Lips, L Mulder, AD Vincent… - Breast cancer research …, 2013 - Springer
Response rates to chemotherapy remain highly variable in breast cancer patients. We set out
to identify genes associated with chemotherapy resistance. We analyzed what is currently …
to identify genes associated with chemotherapy resistance. We analyzed what is currently …
Genomic signature of BRCA1 deficiency in sporadic basal‐like breast tumors
SA Joosse, KIM Brandwijk, L Mulder… - Genes …, 2011 - Wiley Online Library
About 10–20% of all breast carcinomas show a basal‐like phenotype, while ∼ 90% of breast
tumors from BRCA1‐mutation carriers are of this subtype. There is growing evidence that …
tumors from BRCA1‐mutation carriers are of this subtype. There is growing evidence that …
Neoadjuvant chemotherapy in ER+ HER2− breast cancer: response prediction based on immunohistochemical and molecular characteristics
EH Lips, L Mulder, JJ De Ronde, IAM Mandjes… - Breast cancer research …, 2012 - Springer
A pathological complete remission (pCR) is rarely achieved by neoadjuvant chemotherapy
in estrogen receptor-positive (ER+) HER2-negative (HER2−) tumors. Therefore, its use might …
in estrogen receptor-positive (ER+) HER2-negative (HER2−) tumors. Therefore, its use might …
BRCA1 Loss Preexisting in Small Subpopulations of Prostate Cancer Is Associated with Advanced Disease and Metastatic Spread to Lymph Nodes and Peripheral …
…, A Semjonow, M Rink, A Andreas, L Mulder… - Clinical Cancer …, 2010 - AACR
Purpose: A preliminary study performed on a small cohort of multifocal prostate cancer (PCa)
detected BRCA1 allelic imbalances among circulating tumor cells (CTC). The present …
detected BRCA1 allelic imbalances among circulating tumor cells (CTC). The present …
[HTML][HTML] Comprehensive characterization of pre-and post-treatment samples of breast cancer reveal potential mechanisms of chemotherapy resistance
M Hoogstraat, EH Lips, I Mayayo-Peralta, L Mulder… - NPJ Breast …, 2022 - nature.com
When locally advanced breast cancer is treated with neoadjuvant chemotherapy, the recurrence
risk is significantly higher if no complete pathologic response is achieved. Identification …
risk is significantly higher if no complete pathologic response is achieved. Identification …
[HTML][HTML] Prognostic value of histopathological DCIS features in a large-scale international interrater reliability study
EJ Groen, J Hudecek, L Mulder, M van Seijen… - Breast cancer research …, 2020 - Springer
Purpose For optimal management of ductal carcinoma in situ (DCIS), reproducible
histopathological assessment is essential to distinguish low-risk from high-risk DCIS. Therefore, we …
histopathological assessment is essential to distinguish low-risk from high-risk DCIS. Therefore, we …
